How much funding has Tissium raised?

Tissium has raised $164.0M in total funding, most recently a Series D round.

Who are Tissium's investors?

Tissium's investors include Cathay Capital, Mérieux Equity Partners, BNP Paribas Développement, Credit Mutuel Innovation, Sofinnova Partners, Wellington Management.

Where is Tissium headquartered?

Tissium is headquartered in Paris, France.

What industry is Tissium in?

Tissium operates in Biotech, Healthcare.

Tissium

Biomorphic Programmable Polymers

Paris, France · Founded 2013 · $164.0M raised

Biotech

Healthcare

Headquarters: Paris
Employees: 51–200
Founded: 2013
Business Model: B2B

Website: tissium.com
Total Funding: $164.0M
Last Round: $59.0M Series DAug 2021
Rounds: 3

About

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of their first polymer at the labs of Bob Langer and Jeff Karp at MIT, the company recognized the exceptional potential for their technology to revolutionize tissue reconstruction across multiple therapeutic areas. TISSIUM has developed a fully integrated innovation, design, commercialization and manufacturing platform based on proprietary biomorphic programmable polymers, activation technologies, and delivery devices. Their lead product, COAPTIUM CONNECT, received FDA De Novo marketing authorization for peripheral nerve repair. The pipeline also includes ECLIPSIUM for hernia repair and a cardiovascular sealing program.

Summary

Tissium is a Biotech company based in Paris, France, founded in 2013. It has raised $164.0M in total across 3 rounds, most recently a $59.0M Series D round in Aug 2021. Investors include Cathay Capital, Mérieux Equity Partners and BNP Paribas Développement.